ERBB2 and breast carcinoma: The ARTemis trial was designed to test the hypothesis that adding bevacizumab (Bev) [1, 2] to standard neoadjuvant chemotherapy would improve pathological complete response rates (pCR), and longer-term outcomes for HER2 negative early breast cancer.